

Preliminary Programme 2026

The programme may slightly change, depending on new scientific data that is presented in the near future.

All speakers are to be confirmed

Thursday 30th April 2026

09:00 – 09:10	APCCC 2026 Welcome and Opening	Silke Gillessen Aurelius Omlin	10 Minutes
9:10 - 11:30 Session 1	High-risk and locally advanced prostate cancer	Chairs: Pierre Blanchard and Edward Schaeffer	Duration 140 min
What is relevant from a patient's perspective?		André Deschamps	10 min
Histopathology in high-risk and locally advanced prostate cancer		Glen Kristiansen	10 min
Are we overtreating patients based on more accurate imaging (mpMRI and/or PSMA PET)?			
How reliable is imaging to predict histopathology?		Derya Tilki	10 min
Debate: Patients with high-risk localised prostate cancer need the addition of an ARPI to RT plus long-term ADT			
Pro addition of ARPI to RT plus ADT		Christopher J. Sweeney	8 min
Contra addition of ARPI to RT plus ADT		Jeff Michalski	8 min
Arbiter: Balancing Perspectives: Navigating the Addition of ARPI to RT plus ADT		Bertrand F. Tombal	4 min
Q&A (15 min)			
In which patients with high-risk disease may surgery alone be enough and is there any added value of surgery if done as part of multimodality treatment in this setting?		Declan G. Murphy	10 min
Can genomics/AI help to minimize over- or undertreatment?		Jason A. Efstathiou	10 min
The importance of baseline testosterone and testosterone recovery in this setting		Bertrand F. Tombal	10 min
How to treat older patients with high-risk and locally advanced prostate cancer		Rana R. McKay	10 min
Q&A (15 min)			
Discussion of APCCC 2026 voting results (20 min)			
11:30 – 12:00 COFFEE BREAK			
12:00 – 13:05 Session 2 part 1	Treatment for PSA recurrence/persistence	Chairs: Neal Shore and Valerie Fonteyne	Duration 65 min
What is relevant from a patient's perspective?		Eric Briers	10 min
PSA persistence or recurrence after RP – When and how to react?		Jochen Walz	10 min
PSA recurrence after RT – When and how to react?		Pierre Blanchard	10 min

Debate: Early salvage RT is equivalent to adjuvant RT in patients with high-risk localised or locally advanced disease			
Pro		Chris Parker	8 min
Con		Daniel E. Spratt	8 min
Arbiter: Balancing perspectives and practical recommendations for daily practice		Phil Cornford	4 min
Q&A (15 min)			
13:05 – 14:15			
LUNCH			
14:15-15:20 Session 2 part 2	Treatment for PSA recurrence	Chairs: Neal Shore and Valerie Fonteyne	Duration 65 min
	Are there patients with PSA recurrence who don't need imaging and treatment?	Edward Schaeffer	10 min
	Which patients planned for SRT need systemic therapy and for how long?	Piet Ost	10 min
	In which patients is metastases-directed therapy without systemic therapy sufficient?	Kosj Yamoah	10 min
Q&A (15 min)			
Discussion of APCCC 2026 voting results (20 min)			
15:20 – 15:50			
COFFEE BREAK			
15:50– 17:50 Session 3 part 1	Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs: Darren M. C. Poon and Christopher J. Sweeney	Duration 120 min
	Dissecting mHSPC – What are relevant subgroups today and in the future that are relevant for treatment decision?	Ana Aparicio	10 min
	How relevant is rPFS from a patient's perspective?	David Matheson	10 min
	In mHSPC trials, how relevant is rPFS as a primary endpoint from a statistical point of view?	Marc Buyse	5 min
	In mHSPC trials, how relevant is rPFS as a primary endpoint from a clinical point of view?	Ian D. Davis	5 min
	What role plays quality of life in this setting?	Yüksel Ürün	5 min
Q&A (15 min)			
Depending on whether PSMAaddition has been reported/presented or not we will have debate 1 or 2			
Option 1 Debate: Triplet systemic therapy (ADT + Docetaxel + ARPI) is the standard of care in synchronous mHSPC for chemotherapy fit patients?			
Option 2 Debate: Triplet systemic therapy (ADT + 177Lu-PSMA + ARPI) is the standard of care for patients with mHSPC?			
• Pro		Karim Fizazi	8 min
• Contra		Robert J. Jones	8 min
Radiation therapy of the primary in patients with high-volume mHSPC		Tyler Seibert	10 min

How to test for relevant molecular alterations in mHSPC?	Joaquin Mateo	10 min
How to select patients with mHSPC for ADT plus and ARPI plus a targeted therapy?	Shahneen Sandhu	10 min
Q&A (20 min)		
17:50 END OF DAY ONE & NETWORKING APERITIVO		

Friday 1 st May 2026			
Extra session 08:30 - 08:50	Movember Session	Chair: TBD	Duration 20 min
TBC by MOVEMBER		TBD	15 min
Q&A (5min)			
09:00 – 10:45 Session 3 part 2	Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs: Neha Vapiwala and Ignacio Duran	Duration 105 min
Optimal management of synchronous oligometastatic HSPC on PSMA PET		Brandon A. Mahal	10 min
Optimal management of metachronous oligometastatic HSPC on PSMA PET		Nick van As	10 min
Considerations for selection of ARPIs in older patients with mHSPC		Dana Rathkopf	10 min
Q&A (15 min)			
Practical recommendations for physical exercise in patients starting on long-term systemic therapies		Charles J. Ryan	10 min
Practical recommendations for nutrition in patients starting on long-term systemic therapies		Maria De Santis	10 min
Update on de-escalation strategies: in which patients and when can we stop the treatment?		Mika P. Matikainen	10 min
Q&A (15 min)			
Discussion of APCCC 2026 voting results (15 min)			
10:45 – 11:15 COFFEE BREAK			
11:15 – 13:05 Session 4	Management and prevention of frequent side effects and modifying the metabolism	Chairs: Karim Fizazi and Jochen Walz	Duration 106 min
What side effects are most relevant from a patient's perspective?		Brian Jones	10 min
How to address and manage urinary incontinence after RP ± postoperative RT or primary RT		Nicola Fossati	8 min
Prevention and management of RLT induced xerostomia		Daniela Oprea-Lager	8 min
What is the evidence for using metformin in advanced prostate cancer?		Anthony Joshua	8 min
What is the evidence for using statins or low-dose aspirin in advanced prostate cancer?		Lisa G. Horvath	8 min
Q&A (15 min)			
Is there a role for transdermal oestradiol instead of LHRH analogues in patients with advanced prostate cancer?		Noel Clarke	8 min
What to expect from androgen receptor antagonist monotherapy in terms of side-effects and HRQoL?		Fred Saad	8 min
Bone protection in patients with HSPC starting on long-term ADT and in patients with mCRPC		Matthew Smith	8 min
Q&A (10 min)			

Discussion of APCCC 2026 voting results (15 min)			
13:05 – 14:15 LUNCH			
14:15 – 16:15 Session 5	Management of metastatic CRPC	Chairs: Joe M. O’Sullivan and Ravindran Kanesvaran	Duration 120 min
What is relevant from a patient’s perspective when the cancer is no longer responding to testosterone suppression?		Alfred Samuels	10 min
ARPI plus PARP-inhibition – in which patients?		Elena Castro	10 min
The statistical view of the three trials (ARPI + PARP inhibition)		Susan Halabi	10 min
Androgen receptor alterations – what is relevant in the clinic? To cover: Is it important to detect them? Mutations, which predict response/resistance to current treatments, AR degraders, CYP11 inhibitor, splice variants		Gerhardt Attard	10 min
Q&A (15 min)			
Bipolar androgen therapy is there an indication to use it today?		Andrew J. Armstrong	10 min
Oligometastatic CRPC – what is the evidence for SBRT?		Thomas Zilli	10 min
Are there patients with mCRPC who may benefit from immunotherapy?		Emmanuel S. Antonarakis	10 min
Small cell prostate cancer – Treatment options 2026		Himisha Beltran	10 min
Q&A (10 min)			
Discussion of APCCC 2026 voting results (15 min)			
16:15 – 16:45 COFFEE BREAK			
16:45 – 17:50 Session 6	How do we ensure everyone gets the best possible care in different contexts?	Chairs: Nicholas D. James and Omolara A. Fatiregun	Duration 65 min
Drug repurposing and drug optimization		Diogo Assed Bastos	5 min
How to address inequalities in access driven by societal factors – the UK perspective		Nicholas D. James	5 min
How to address inequalities in access driven by societal factors – the US perspective		Brandon A. Mahal	5 min
How to address inequalities in access driven by societal factors – the African perspective		Omolara A. Fatiregun	5 min
How to address inequalities in access driven by societal factors – the Indian perspective		Vedang Murthy	5 min
How to improve representation of minorities in clinical trials		Alfred Samuels	5 min
What is the role of societies (ASCO, ESMO) in defining optimal care?		Eric J. Small	5 min
How can charities address inequalities?		Amy Rylance (prostate cancer UK)	5 min
How to address inequalities in access driven by lack of specialist knowledge		Stacy Loeb	5 min
Is there a possibility to make NGS testing/results widely available?		Colin C. Pritchard	5 min
Is there a possibility to make PET imaging and theranostics widely available?		Stefano Fanti	5 min



ADVANCED PROSTATE CANCER
CONSENSUS CONFERENCE APCCC 2026
LUGANO
30 April – 2nd May 2026
apccc.org

Q&A (10 min)
17:50
End of Day 2

Saturday 2 nd of May 2026			
09:00 – 10:10 Session 7	Monitoring	Chairs: Anwar R. Padhani and Matthew Smith	Duration 70 min
	Monitoring in mHSPC	Maha H. A. Hussain	10 min
	Monitoring in mCRPC	Gunhild von Amsberg	10 min
	How can electronic tools be used for monitoring of patients with advanced prostate cancer	Alicia K. Morgans	10 min
	Is there a role for the routine use of ctDNA in advanced prostate cancer?	Kim N. Chi	10 min
Q&A (15min)			
Discussion of APCCC 2026 voting results (15 min)			
10:10- 10:40 COFFEE BREAK			
10:40 – 12:15 Session 8	Radioligand and radionuclide therapy in advanced prostate cancer	Chairs: A. Oliver Sartor and Maria De Santis	Duration 95 min
	Patients' expectations for radioligand therapy	Fabrice Bossaert	10 min
	How to optimally select patients for Lutetium-PSMA radioligand therapy?	Michael J. Morris	10 min
	How to make best use of Lutetium-PSMA RLT?	Louise Emmett	10 min
Q&A (10 min)			
	How to optimally select patients for radionuclide therapy with radium-223?	Daniel Heinrich	10 min
	PSMA plus: New tracers and equipment technologies to improve accuracy that are close to clinical implementation	Ken Herrmann	10 min
	New theranostic concepts – what can we expect in the near future?	Michael S. Hofman	10 min
Q&A (10 min)			
Discussion of APCCC 2026 voting results (15 min)			
12:15 Closing Remarks: Silke Gillessen and Aurelius Omlin			